Trials of inhaled Iloprost and other new vasodilating prostaglandins

Higenbottam T., Siddons T.

Source: Eur Respir J 2001; 17: 6-7

Journal Issue: January

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Higenbottam T., Siddons T.. Trials of inhaled Iloprost and other new vasodilating prostaglandins. Eur Respir J 2001; 17: 6-7

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1037-1049 Year: 2002
Late-breaking abstract: Urinary leukotriene E₄/exhaled nitric oxide ratio as a predictor of exercise-induced bronchoconstriction control by oral montelukast or inhaled corticosteroid Source: Annual Congress 2011 - Coping and lifestyle in childhood asthma Year: 2011
Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002
Protective effect of inhaled iloprost on exercise-induced bronchoconstriction Source: Eur Respir J 2004; 24: Suppl. 48, 443s Year: 2004
Comparative effects of inhaled nitric oxide and aerosolized iloprost during vasoreactivity testing in chronic pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005
Inhaled iloprost plus oral sildenafil in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001
Differential action of beraprost isomers on prostacyclin (IP) receptors and PPARβ in pulmonary arteries Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015
Combination of inhaled nitric oxide and an endothelin_A-receptor antagonist in acute pulmonary thromboembolism Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003
Emerging inhaled bronchodilators: an update Source: Eur Respir J 2009; 34: 757 Year: 2009
Anti-inflammatory effects of histamine H₁-receptor antagonist and leukotriene CysLT₁-receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004
Abediterol has higher bronchodilatory potency and reduced cardiac effects versus other long-acting beta₂-agonists in dogs Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006
Effect of once-daily inhaled glucocorticosteroid administration on exhaled nitric oxide in controlled asthma patients Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Effect of inhaled steroids and long-acting β2 agonists on exhaled nitric oxide (eNO) in asthmatic children Source: Eur Respir J 2004; 24: Suppl. 48, 270s Year: 2004
Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 339-343 Year: 2002
Onset of action of inhaled corticosteroids on bronchial and alveolar nitric oxide output Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020
Inhaled iloprost for the treatment of pulmonary hypertension Source: Eur Respir Rev 2009; 18: 29-34 Year: 2009
PDE 3/4 inhibition prolonges pulmonary vasodilatory response to inhaled iloprost Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001